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Expression of messenger molecules and
receptors in rat and human sphenopalatine
ganglion indicating therapeutic targets
Anna Steinberg1,4* , Simona D Frederiksen2, Frank W Blixt2, Karin Warfvinge2,3 and Lars Edvinsson2,3
Abstract
Background: Migraine and Cluster Headache (CH) are two primary headaches with severe disease burden. The
disease expression and the mechanisms involved are poorly known. In some attacks of migraine and in most
attacks of CH, there is a release of vasoactive intestinal peptide (VIP) originating from parasympathetic cranial
ganglia such as the sphenopalatine ganglion (SPG). Patients suffering from these diseases are often deprived of
effective drugs. The aim of the study was to examine the localization of the botulinum toxin receptor element
synaptic vesicle glycoprotein 2A (SV-2A) and the vesicular docking protein synaptosomal-associated protein 25
(SNAP25) in human and rat SPG. Additionally the expression of the neurotransmitters pituitary adenylate cyclase
activating polypeptide (PACAP-38), nitric oxide synthase (nNOS), VIP and 5-hydroxttryptamine subtype
receptors (5-HT1B,1D,1F) were examined.
Methods: SPG from adult male rats and from humans, the later removed at autopsy, were prepared for
immunohistochemistry using specific antibodies against neurotransmitters, 5-HT1B,1D,1F receptors, and
botulinum toxin receptor elements.
Results: We found that the selected neurotransmitters and 5-HT receptors were expressed in rat and human
SPG. In addition, we found SV2-A and SNAP25 expression in both rat and human SPG. We report that all
three 5-HT receptors studied occur in neurons and satellite glial cells (SGCs) of the SPG. 5-HT1B receptors
were in addition found in the walls of intraganglionic blood vessels.
Conclusions: Recent focus on the SPG has emphasized the role of parasympathetic mechanisms in the
pathophysiology of mainly CH. The development of next generation’s drugs and treatment of cranial
parasympathetic symptoms, mediated through the SPG, can be modulated by treatment with BoNT-A and 5-HT
receptor agonists.
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Background
Migraine and Cluster Headache (CH) are two primary
headaches with severe disease burden. In particular, CH
is an extremely painful disorder characterized by periods
(clusters) of recurrent, unilateral attacks of excruciating
pain with a retro-orbital maximum and attacks lasting
from 15–180 min [1]. CH usually appears between 20
and 40 years of age and during its active phase the at-
tacks occur from once every second day to 8 times a
day. Most patients show ipsilateral symptoms such as
conjunctival injection, lacrimation, nasal congestion, rhi-
norrhoea and forehead/facial sweating, indicating an
ipsilateral parasympathetic dysfunction which has been
proven by co-release of the parasympathetic messenger
molecule VIP [2].
The mechanisms involved in migraine and CH are
considered to differ but also share some aspects [3].
Cranial autonomic symptoms (CAS), i.e. parasympa-
thetic symptoms, occur in both migraine and CH
patients [4–6], indicating involvement of the trigemino-
autonomic reflex with increased parasympathetic out-
flow [5–7], mediated through the sphenopalatine
ganglion (SPG) [8, 9]. Markedly raised levels of VIP and,
in particular, calcitonin gene-related protein (CGRP)
have been measured during spontaneous CH attacks.
These findings were considered as evidence of involve-
ment of the cranial parasympathetic nervous system [2].
In human SPG the parasympathetic signaling transmit-
ters in neural cell bodies consist mainly of VIP, PACAP,
acetylcholine (ACh) and NOS [10].
Onabotulinumtoxin A (BoNT-A), more commonly
known by the trade name Botox®, comes from Clostrid-
ium botulinum. It works by blocking the release of the
neurotransmitter ACh, which has been found in SPG
[11], by cleaving SNAP25, a protein necessary for ACh
release from vesicles in nerve endings [12]. However, it
is unknown if SNAP25, and SV-2A, are expressed in the
SPG. A previous study from our group has shown the
presence of SV-2A and SNAP25 in rat trigeminal gan-
glion (TG) [11]. Incubation with BoNT-A was shown to
reduce the inflammation response elicited by organ cul-
ture of the TG.
Triptans are 5-hydroxytryptamine (5-HT) receptor ag-
onists with a high affinity for the 5-HT1B/1D/1F receptors,
which generally are effective for aborting headache attacks
of both migraine and CH. The multiple mechanism of ac-
tion for 5-HT1B/1D receptors includes vasoconstriction, in-
hibition of the release of vasoactive neurotransmitters by
trigeminal nerves as well as inhibition of nociceptive
neurotransmission [13, 14]. 5-HT1F receptors is character-
ized by lack of vasoconstrictive properties [15]. 5-HT1B,1D
receptors have been localized in the human TG [14–16].
Activation of those receptors seems to be one of the trip-
tans modes of action. Early clinical studies showed effects
in CH [2], thus triptans might have a direct effect on hu-
man SPG.
The aim of the present work was to examine if rat
and human SPG contain the SV2-A and SNAP25 pro-
teins and, by extension, if BoNT-A might have a
mechanism of action in SPG. Secondly, we aimed at
investigating the expression of 5-HT1B,1D,1F receptors
and the SPG neurotransmitters (PACAP-38, nNOS
and VIP). This will provide novel and greater under-
standing of the action mechanisms in the SPG and
could increase the possibility for future drug develop-
ments for CH.
Methods
Wistar or Sprague–Dawley male rats (n Wistar = 9,
n Spraque-Dawley = 10, weight = approx. 250 g) were eutha-
nized by CO2 inhalation followed by decapitation. The
SPG was carefully dissected out, close to the time of
euthanasia, by initially making an incision over the zygo-
matic bone. The zygomatic bone was cut at both extrem-
ities and removed. The exposed deep masseter muscle
was removed. The fifth cranial nerve trunk was revealed,
carefully cut, and pulled posteriorly. The SPG, situated
against the dorsal part of the maxillary bone, is thereby
disclosed. The entire ganglion was carefully dissected and
placed in 4 % paraformaldehyde for 2–4 h, followed by
incubation overnight in Sörensen’s phosphate buffer
(pH 7.2) containing 10 % and 25 % sucrose in turn. There-
after, the tissue was embedded in Yazulla embedding
medium (30 % egg albumin and 3 % gelatin in distilled
water) and 10 μm cryosections were cut in a cryostat
(Thermo Scientific Microm HM560). The sections were
stored at −20 °C until use.
The human SPG was collected at autopsy, within 48 h
post-mortem, from three patients. The patients were
without disorders related to the central nervous system.
The specimens were fixed in 4 % paraformaldehyde
followed by sucrose-cryoprotection in 10 % sucrose
Tyrode solution. The tissue samples were kept at −80 °C
until embedding and cryo-sectioning. The study followed
the guidelines of the European Communities Council
(86/609/ECC) and was approved by the Committee of
the Animal Research of University of Szeged (I-74-12/
2012) and the Scientific Ethics Committee for Animal
Research of the Protection of Animals Advisory Board
(XI./352/2012). The rat study was approved by the
Regional Ethical Committee on Animal Research, Malmö/
Lund, Sweden. (M43-07).
Hematoxylin-Eosin (HE)
Cryosections of rat and human SPG were stained using
Hematoxylin (Htx) and Eosin dyes (Htx 4 min, Eosin
1 min). The staining was done in order to examine the
morphology and condition of the tissue.
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Immunohistochemistry
Rat and human sections were washed in phosphate buff-
ered saline (PBS) containing 0.25 % TritonX (PBS-T)
once for 15 min followed by application of the primary
antibody (Table 1) with incubation overnight at +4 °C in
moisturized incubation chambers. The following day, the
sections were washed twice in PBS-T for 15 min prior to
incubation with secondary antibodies (Table 2) for 1 h in
room temperature. Finally, the sections were washed
2×15 min and mounted with Vectashield mounting
medium containing 4’,6-diamidino-2-phenylindole (DAPI)
(Vector Laboratories, Burlingame CA, USA). Two out
of three human samples were subjected to antigen re-
trieval by 30–60 min incubation at room temperature
and at +75 °C in citrate buffer (10 mM sodium cit-
rate, pH 6) prior to immunohistochemistry.
Double stainings were exclusively performed in rat SPG.
The protocol described above was repeated twice and
done sequentially. Each staining was performed three
times to ensure reproducibility. Omission of primary anti-
bodies served as negative controls. The sections were ex-
amined in an epifluorescence microscope (Nikon 80i,
Tokyo, Japan) equipped with a Nikon DS-2MV camera.
Finally, images were processed using Adobe Photoshop
CS3 (v0.0 Adobe Systems, Mountain View, CA).
Results
Hematoxylin Eosin staining
HE staining of the SPG is shown in Fig. 1. The staining
revealed neurons of different sizes, enveloped by a single
layer of SGCs. These neuron/SGC units were inter-
mingled between fibers. The morphology of the different
rat SPGs was in general good, though minor tissue shrink-
age was observed in some of the SPGs. Human SPG
showed in general somewhat more shrinkage of the tissue.
Rat SPG
Neurotransmitters
PACAP-38 immunoreactivity was found in neurons and
fibers, but individual differences were observed; not all
animals displayed neuronal stainings. PACAP-38 immu-
noreactivity was found in the SGCs in all animals
(Fig. 2a). nNOS was expressed in the cytoplasm of the
neurons and in intraganglionic nerve fibers in a pearl-
like manner around the neurons (Figs. 2b). In contrast
to the homogeneous pattern of cytoplasmic stainings ob-
served with PACAP-38 and nNOS immunohistochemis-
try, VIP immunoreactivity was found in a granular
manner close to the neuronal nuclei, resembling endo-
plasmatic reticulum staining (Fig. 2c). By and large, VIP,
PACAP-38 and nNOS were localized in the SPG neu-
rons, while PACAP-38 alone was expressed in the SGCs.
5-HT receptors
The 5-HT1B receptor expression was found in numerous
neurons and fibers, in addition to the vessel walls
(Fig. 2d). 5-HT1D and 5-HT1F immunoreactivities were
seen in many neurons and nerve fibers, but not in the
vessel walls (Fig. 2e and f).
Table 1 Overview of the primary antibodies
Primary antibody
Product Product ID Host Dilution Detects Company
PACAP-38 T-4473 Rabbit 1:500 Human and rat PACAP-38 Peninsula Laboratories, LLC, San Carlos, CA, USA
nNOS N2280 Mouse 1:2500 NOS derived from brain Sigma Aldrich, St. Louis, MO, USA
VIP (M-19) sc-7841 Goat 1:100 C-terminus of mouse VIP Santa Cruz Biotechnology, Santa Cruz, CA, USA
SNAP-25 S9684 Rabbit 1:100 N-terminus of human SNAP-25 Sigma-Aldrich, St. Louis, MO, USA
SV-2A ab32942 Rabbit 1:1000 Amino acids 1–100 of rat SV2A Abcam, Cambridge, UK
5-HT1B ab13896 Rabbit 1:100 Amino acids 8–26 and 263–278 of 5HT1B Abcam, Cambridge, UK
5-HT1D ab13895 Rabbit 1:100 Amino acids 1–18 and 251–267 of rat 5HT1D Abcam, Cambridge, UK
5-HT1F SP4043P Rabbit 1:200 N-terminus extracellular domain of human 5HT1F Acris Antibodies, San Diego, CA, USA
Table 2 Overview of the secondary antibodies
Secondary antibody
Product Host Against Dilution Company
Alexa Flour 488 Donkey Anti-goat 1:400 Invitrogen, CA, USA
Alexa Flour 594 Goat Anti-mouse 1:200 Invitrogen, CA, USA
Alexa Flour 594 Donkey Anti-rabbit 1:400 Jackson Immunoresearch Laboratories, Inc., West Grove, PA, USA
FITC Donkey Anti-mouse 1:100 Jackson Immunoresearch Laboratories, Inc., West Grove, PA, USA
FITC Goat Anti-rabbit 1:100 Cayman Chemical, Ann Arbor, MI, USA
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Fig. 1 Hematoxylin-Eosin. The staining demonstrates neurons (arrow) and satellite glial cells (arrow heads) surrounding the neurons forming
distinct units
Fig. 2 Rat SPG immunohistochemistry. a PACAP-38 immunohistochemistry. PACAP-38 was found in neurons (thin arrows), fibers (arrow heads),
and very intense in the SGCs (thick arrows). b nNOS was expressed in the cytoplasm of many of the neurons (thin arrows), negative neurons were
also found (asterisk). In addition, immunoreactive pearl-like fibers were observed (arrow heads). c VIP immunoreactivity was disclosed in a granular
manner close to the neuronal nuclei, resembling endoplasmatic reticulum staining (arrows). d Serotonin receptor 5-HT1B expression was found
most neurons (thin arrows) and fibers (arrow heads), in addition to the vessel walls (thick arrows). e 5-HT1D immunoreactivity was seen in many
neurons (arrows) and nerve fibers (arrow heads). f 5-HT1F immunoreactivity was seen in many neurons (arrows) and nerve fibers (arrow heads).
g SNAP25 immunoreactivity was found in neurons (thin arrows) in the same granular pattern as described for VIP above. In addition, nerve fibers were
immunoreactive (arrow heads). h SV2-A immunoreactivity was exclusively found in the SGCs (arrows)
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SNAP25 and SV2-A
SNAP25 immunoreactivity was found in most neurons
in the same granular pattern as described for VIP above,
but not in SGCs. In addition, nerve fibers were immuno-
reactive (Fig. 2g). SV2-A immunoreactivity was only
found in the SGCs (Fig. 2h).
Double stainings
Co-localizations were found on one hand between
nNOS and 5-HT1B (Fig. 3a), 5-HT1D (Fig. 3b), 5-HT1F
(Fig. 3c) and SNAP25 (Fig. 3d) on the other. SV2-A did
not co-localize with either nNOS (Fig. 3e) or VIP in neu-
rons (Fig. 3f ).
Summary of immunohistochemistry results are shown
in Fig. 4.
Human SPG
Individual differences were observed between the human
samples in all stainings; two of the three specimens
needed antigen retrieval to get the antibodies to recognize
the antigen. In addition, many neurons in the human
material contained intense autofluorescent lipofuscin in
their cytoplasm
Neurotransmitters
PACAP-38 immunoreactivity was disclosed in some neu-
rons, in nerve fibers and in vessel walls (Fig. 5a). nNOS
immunoreactivity was found in neurons (Fig. 5b).
5-HT receptors
5-HT1B immunoreactivity was found in most neurons,
in some fibers and in vessel walls (Fig. 5d and e). 5-
HT1D immunoreactivity was seen in neurons and fibers
(Fig. 5f and g). 5-HT1F immunoreactivity was not ob-
served in the human material (using the available
antibodies).
SNAP25 and SV2-A
SNAP25 immunoreactivity was exclusively observed in
SGSs (Fig. 5h and i), while the SV2-A immunoreactivity
was confined to neurons (Fig. 5j and k).
Discussion
The present study is the first to examine the co-
expression of signalling molecules and receptor elements
in human and rat SPG. It is well known that triptans
have clinically positive effects on acute pain in CH [17].
Thus, we asked the question if 5-HT1B, 5-HT1D and 5-
HT1F receptors are expressed in neurons and SGCs in
Fig. 3 Rat SPG immunohistochemistry – double staining. a nNOS and 5-HT1B double staining revealed neurons that expressed either nNOS
(thin arrows) or 5-HT1B (asterisk), but also both (thick arrows). Fibers were mostly nNOS positive (thin arrow head). Thick arrow heads point at 5-
HT1B positive vessels. b nNOS and 5-HT1D double staining revealed neurons that expressed either nNOS (thin arrows) or 5-HT1D (asterisk), but also
both (thick arrows). The same pattern was found for the fibers; nNOS positive (thin arrow head), 5-HT1D (two asterisks) or double stained (thick
arrow head). c nNOS and 5-HT1F double staining revealed neurons that expressed either nNOS (thin arrows) or 5-HT1F (asterisk), but also both (thick
arrows). d Double staining with nNOS and SNAP25 revealed that all nNOS immunoreactive neurons were also positive for SNAP25 (thin arrows).
In addition, nNOS positive fibers were SNAP25 positive (arrow heads). SNAP25 immunoreactivity was found in most cells (thick arrows). e and
f SV2-A (arrow heads) did not co-localize with either nNOS (thin arrows) or VIP (thin arrows). All images are shown with the same magnification
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SPG. Importantly, we report that 5-HT1B, 5-HT1D and
5-HT1F receptors are expressed on most neurons in the
rat SPG, which correlates well with the clinical effective-
ness of triptans in CH. Here we demonstrate that all
three 5-HT receptor subtypes occur in neurons and
SGCs of the rat SPG. However, the 5-HT1F receptor was
only found in rodent material, possibly due to the anti-
genic properties of the used antibody. In addition 5-
HT1B receptors occur in the intraganglionic blood ves-
sels, putatively indicating a possible vasomotor role.
Previous studies have revealed expression of the para-
sympathetic signaling transmitters VIP, PACAP and
nNOS in rat [18] and human [19] SPG. The results in
the present study are in concert with these earlier studies.
We found that both species contain SV2-A and SNAP25,
elements involved in ACh neurotransmission, which has
not been described earlier, however with a mixed expres-
sion. In rat, SNAP25 was expressed in neurons and fibers,
but with SV2-A in the SGCs. In humans, SNAP25 was
expressed in the SGCs, but SV2-A in the neurons.
SNAP25 was mainly seen in the SGCs, while in man the
neurons expressed Botox receptors elements SV2-A
(opposite in rat). This could indicate that some effect of
BoNT-A could occur in SPG provided it reaches this
structure. The anatomical proximity of facial/temporal
injection sites of BoNT-A in the PREEMPT protocol is
much closer to the SPG than to the TG. The significance
of the differential expression of SNAP25 and SV2-A is un-
clear but perhaps the localization of the receptor elements
might suggest a potential target site of botulinum toxin if
it has access to the receptor site.
Treatment with BoNT-A in adults with chronic mi-
graine (CM) has shown safety and efficacy [20, 21]. Pilot
studies of SPG injection of BoNT-A for treatment of
CM as well as in chronic CH (CCH) have showed prom-
ising results [22, 23]. A previous study has shown pres-
ence of SV-2A and SNAP25 protein with same location
in the TG [11]. The present results illustrate a possible
site/mechanism of action for BoNT-A in CH. There is
however no data available for an effect of BoNT-A in
CH. The work provides anatomical rationale for this
possibility, and given the proximity of the SPG to in-
jection sites used in BoNT-A therapy it might be
considered at least. Recent work has focused on neu-
romodulation of the SPG using e.g. specific SPG
stimulation [24, 25].
An issue for the present work is if BoNT-A has a the-
oretical possibility to work as medical prophylaxis in
CH. Earlier studies have shown varying results regarding
BoNT-A as prophylactic treatment for CH. Twelve CCH
patients were included in an open study where BoNT-A
was given as an add-on therapy, i.e. prior prophylactic
medication was continued [26]. BoNT-A was injected
according to a standardised protocol, ipsilateral to the
pain. Four of the twelve patients showed improve-
ment [26]. A pilot study where BoNT-A was injected
towards the SPG in CCH patients showed at least
50 % reduction of attack frequency in five out of ten
patients [27]. So far, no randomised, placebo-controlled
study regarding BoNT-A and treatment of CH has been
performed.
Triptans were early found to abort CH attacks [28–30].
It was not until fairly recently that Ivanusic (2011) re-
ported 5-HT1D receptor immunoreactivity in nerve termi-
nals around neurons in the rat SPG. These fibers were all
CGRP positive and thus sensory in nature. They were
traced back to the TG. Csati et al. (2012) showed CGRP
positive fibers also in the human SPG, which agrees well
with the present study.
Triptans are 5-HT1B/1D receptor agonists with high
affinity for 5-HT1B/1D receptors, which are generally ef-
fective for aborting attacks in both migraine and CH.
The multiple mechanism of action for 5-HT1B/1D recep-
tors includes vasoconstriction, inhibition of the release
of vasoactive neuropeptides by trigeminal nerves as well
as inhibition of nociceptive neurotransmission [13, 14].
Both 5-HT1B/1D receptors have been localized in the
human TG [14, 16]. Activation of those receptors
seems to be one of the triptans modes of action.
Fig. 4 Overview over results found in rat SPG. The left side
demonstrates antibody expression in the neurons and the right
side in the SGCs. Only PACAP38 was found in both neurons and
SGCs. SV2-A was only found in the SGCs
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Fig. 5 Human SPG immunohistochemistry. a PACAP-38 immunoreactivity was found in some neurons (thin arrows), in fibers (thick arrow) and
vessel walls (thin arrow head). Yellow represent autofluorescent lipofuscin in the neurons (thick arrow head). b nNOS immunoreactivity was found
in the neurons (thin arrows) and vessel walls (thin arrow head). Thick arrow points at a negative cell. Yellow; autofluorescent lipofuscin (thick arrow
head). All images are in the same magnification. c and d 5-HT1B immunoreactivity was found in most neurons (thin arrows), and in some
fibers (thin arrow heads) and vessel walls (thick arrow). Asterisk indicates a negative cell. Yellow; autofluorescent lipofuscin (thick arrow heads).
e and f 5-HT1D immunoreactivity was seen in neurons (thin arrows) and fibers (thin arrow heads). Yellow; autofluorescent lipofuscin (thick arrow
head) g and h SNAP25 immunoreactivity was exclusively found in SGCs (thin arrow heads). Yellow; autofluorescent lipofuscin (thick arrow head).
i and j SV2-A immunoreactivity was confined to neurons (thin arrows). Asterisk indicates a negative cell. Yellow; autofluorescent lipofuscin (thick
arrow head). The same magnifications are used throughout the panel (c-j)
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Triptans might have a direct effect on human SPG.
So far, the issue has to be answered. We showed 5-
HT1B and 5-HT1D immunoreactivity in SPG neurons,
which suggests a role in modifying the activity in
SPG. The variability in the 5-HT1F expression is likely
due to low specificity of these antibodies species. This
issue is under current development.
Some limitations of our study need to be addressed.
The human material is restricted to three SPG obtained at
autopsy, due to difficulties to obtain those structures. Fur-
ther, although the material has been carefully processed,
we cannot exclude postmortem changes. In addition, our
findings are purely anatomical and the question as to
function may be addressed in subsequent work.
Conclusion
Theoretically, our work provides anatomical indication,
that both triptans and BoNT-A may have an effect on
the SPG. Further randomised, placebo-controlled studies
regarding especially BoNT-A treatment of CH are
warranted. In addition this study also provides evidence
for triptan effects in the SPG.
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